AMENDMENT NO. 1 TO THE LICENSE AGREEMENTLicense Agreement • April 16th, 2024 • Windtree Therapeutics Inc /De/ • Biological products, (no disgnostic substances)
Contract Type FiledApril 16th, 2024 Company IndustryThis Amendment No. 1 to the License Agreement (this “Amendment”), dated January 17, 2024 (the “Amendment Effective Date”), is made by and between Windtree Therapeutics, Inc., a Delaware corporation formerly known as Discovery Laboratories, Inc. (“Windtree”), and Philip Morris Products S.A., a Switzerland corporation (“PMPSA”). Windtree and PMPSA are sometimes referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • April 16th, 2024 • Windtree Therapeutics Inc /De/ • Biological products, (no disgnostic substances) • England and Wales
Contract Type FiledApril 16th, 2024 Company Industry JurisdictionThis License, Development and Commercialization Agreement (this “Agreement”) is entered into as of January 7, 2024 (the “Effective Date”), by and between Windtree Therapeutics, Inc., a Delaware corporation with its principal offices at 2600 Kelly Rd., Suite 100, Warrington, PA 18976 USA (“Licensor”), and Lee’s Pharmaceutical (HK) Ltd., a Hong Kong company organized and existing under the laws of Hong Kong with its principal offices at 1/F, Building 20E, Phase 3, Hong Kong Science Park, Shatin, Hong Kong (“Licensee”). Licensor and Licensee are sometimes referred to in this Agreement individually as a “Party” and together as the “Parties.”
AMENDMENT NO. 1 TO AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • April 16th, 2024 • Windtree Therapeutics Inc /De/ • Biological products, (no disgnostic substances)
Contract Type FiledApril 16th, 2024 Company IndustryThis Amendment No. 1 to Amended and Restated License Agreement (this “Amendment”), dated January 17, 2024 (the “Amendment Effective Date”), is made by and between Windtree Therapeutics, Inc., a Delaware corporation formerly known as Discovery Laboratories, Inc. (“Windtree”), and Philip Morris USA Inc., a Virginia corporation formerly referred to as Philip Morris USA Inc., d/b/a Chrysalis Technologies (“PM USA”). Windtree and PM USA are sometimes referred to in this Agreement individually as a “Party” and collectively as the “Parties.”